source
- Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliencyWhile Novartis’ Pluvicto is a blockbuster, Curium heads into talks with the FDA about the review of its rival drug candidate believing a competing product can make the supply chain more resilient.BioSpace · 40m ago↗ source
- Roche's Genentech signs up to $2.3B deal with Hanmi for weight-loss drug that preserves lean massRoche, through its Genentech subsidiary, has entered a licensing agreement with South Korea's Hanmi Pharm that could be worth up to $2.3 billion, including a $190 million upfront payment. The deal…